S&P 500 Index

+4.82 (+0.09%)
StockTwits Share  Twitter Share  Facebook Share

Novo Nordisk Reports Strong Q1 Results and Raises Full-Year Outlook on Weight-Loss Drug Demand

Date Published:
Author: CML News


Novo Nordisk has increased its full-year sales and operating profit outlook at constant exchange rates, driven by strong sales growth of weight-loss drug Wegovvy in the first quarter.



  • Novo Nordisk has raised its forecast for full-year sales and operating profit at constant exchange rates.
  • In Q1, the company's operating profit increased by 28% on sales growth of 25% at constant exchange rates.
  • The increase in operating profit and sales outlook is mainly attributed to the prescription trends for weight-loss drug Wegovvy.
  • Novo Nordisk now expects operating profit growth between 28% and 34% on sales growth between 24% and 30%, compared to its earlier view of 13% to 19% growth in both operating profit and sales for the year.
  • Credit Suisse upgraded the stock earlier, citing Ozempic growth acceleration and Wegovy re-launch as contributing factors to the positive outlook.

Stock Charting as a Science

CML Pattern Finder is the answer. It takes the guesswork and time out of understanding stock charts and screening for traders.

Transform a standard stock chart into a trading plan — instantly. We mean that - it takes less than 3 seconds for the platform to take a stock chart and apply algorithms to show congestion, support, resistance, and moat, importantly target zones.

You have to experience it to believe and experience is just a (free) click away below

Leverage the market like a pro, and keep leveraging it, all for less than $1 a day.

We are offering a huge discount on this page: Pattern Finder: The Next Era of Charting